Amgen Inc on Wednesday said it filed with U.S. health regulators seeking approval to sell its first biosimilar drug, which would be a less expensive alternative to AbbVie's Humira, the world's top-selling prescription medicine.
Amgen said its drug, ABP 501, has demonstrated clinical equivalence and comparable safety to Humira (adalimumab) in late stage clinical trials for rheumatoid arthritis and the skin condition plaque psoriasis.
03:35 Ivan Rodriguez, Tim Raines and Jeff Bagwell prove Hall of Fame does forgive14
21:52 Netflix nears 94 million subscribers 10 years after streaming launch13
18:21 Mark Zuckerberg takes the stand in $2 billion lawsuit claiming Oculus theft7
16:16 Luxottica, Essilor $24 billion merger creates eyewear giant18